abstract |
The use is provided of a soluble receptor that binds to an IL-20 polypeptide, wherein the IL-20 polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8 and 9, for the manufacture of a medicament for treating an inflammatory disease, wherein said soluble receptor comprises: a first subunit, said first subunit comprising an amino acid sequence selected from SEQ ID NOs: 11, 12, 55, 63 and 65, or a fragment thereof that binds to an IL-20 polypeptide; and a second subunit, said second subunit comprising an amino acid sequence selected from SEQ ID NOs: 14, 15, 19, 59, 61, 67, 68 and 69, or a fragment thereof that binds to an IL-20 polypeptide; wherein said inflammatory disease is an inflammatory lung disease, an inflammatory bowel disease, systemic lupus erythematosis, rheumatoid arthritis, idiopathic pulmonary fibrosis, septic shock or multiple organ failure. |